scholarly journals Caspase-dependent drug-induced apoptosis is regulated by cell surface sialylation in human B-cell lymphoma

2015 ◽  
Vol 10 (2) ◽  
pp. 687-690 ◽  
Author(s):  
OSAMU SUZUKI ◽  
MASAFUMI ABE ◽  
YUKO HASHIMOTO
Keyword(s):  
Cell Surface ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Drug Induced ◽  
Induced Apoptosis ◽  
Human B Cell

Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma

Cell ◽  
1986 ◽  
Vol 44 (1) ◽  
pp. 97-106 ◽  
Author(s):  
Michael L. Cleary ◽  
Timothy C. Meeker ◽  
Shoshana Levy ◽  
Elizabeth Lee ◽  
Martha Trela ◽  
...  
Keyword(s):  
B Cell ◽  
Heavy Chain ◽  
Somatic Mutations ◽  
Cell Lymphoma ◽  
Variable Region ◽  
B Cell Lymphoma ◽  
Chain Gene ◽  
Heavy Chain Gene ◽  
Immunoglobulin Heavy Chain Gene ◽  
Human B Cell

scholarly journals CD81 is a novel immunotherapeutic target for B cell lymphoma

2019 ◽  
Vol 216 (7) ◽  
pp. 1497-1508 ◽  
Author(s):  
Felipe Vences-Catalán ◽  
Chiung-Chi Kuo ◽  
Ranjani Rajapaksa ◽  
Caroline Duault ◽  
Noemi Andor ◽  
...  
Keyword(s):  
B Cell ◽  
Therapeutic Potential ◽  
Cell Lymphoma ◽  
Xenograft Model ◽  
B Cell Lymphoma ◽  
Lymphoid Cells ◽  
Antiproliferative Effects ◽  
Biopsy Specimens ◽  
Human Lymphoma ◽  
Human B Cell

The tetraspanin CD81 was initially discovered by screening mAbs elicited against a human B cell lymphoma for their direct antiproliferative effects. We now show that 5A6, one of the mAbs that target CD81, has therapeutic potential. This antibody inhibits the growth of B cell lymphoma in a xenograft model as effectively as rituximab, which is a standard treatment for B cell lymphoma. Importantly, unlike rituximab, which depletes normal as well as malignant B cells, 5A6 selectively kills human lymphoma cells from fresh biopsy specimens while sparing the normal lymphoid cells in the tumor microenvironment. The 5A6 antibody showed a good safety profile when administered to a mouse transgenic for human CD81. Taken together, these data provide the rationale for the development of the 5A6 mAb and its humanized derivatives as a novel treatment against B cell lymphoma.

Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody

1991 ◽  
Vol 32 (6) ◽  
pp. 364-372 ◽  
Author(s):  
A. Hekman ◽  
A. Honselaar ◽  
W. M. J. Vuist ◽  
J. J. Sein ◽  
S. Rodenhuis ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Initial Experience ◽  
Human B Cell
Sign in / Sign up

Export Citation Format

Share Document